{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:31:00Z","timestamp":1762162260179,"version":"build-2065373602"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Total neoadjuvant treatment (TNT) has become the standard of care for locally advanced rectal cancer (LARC), leading to increased rates of complete clinical response and expanding the potential for organ preservation through non-operative management (NOM) protocols. Despite these advances, tumor regrowth remains a concern, necessitating vigilant surveillance to ensure early detection. However, adherence to surveillance protocols is often suboptimal, and the factors influencing tumor regrowth during NOM have not been well defined. This study aims to identify predictors of tumor regrowth in patients undergoing NOM after TNT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective review of patients with LARC who completed TNT at a single institution between 2019 and 2024. Patients who achieved sustained complete clinical response (cCR) for at least 12 months, as well as those who experienced tumor regrowth following cCR, were included. Patients with suspected regrowth who subsequently underwent surgery and were found to have a pathologic complete response (pCR) were excluded. Univariate analyses were performed to compare demographic, histopathologic, biochemical, clinical, radiological, and treatment-related factors between patients who experienced tumor regrowth and those who did not. The primary objective of our study was to identify predictors of tumor regrowth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 137 patients with LARC, 44 patients (32.1%) achieved cCR following completion of TNT. Of these, 10 patients experienced tumor regrowth and subsequently underwent surgery, with histopathology revealing a pCR in 2 cases. Currently, 11 patients remain in their first year of NOM, and 3 patients were lost to follow-up. In total, 20 patients sustained cCR. A total of 28 patients (25% female) with a mean age of 62.4 years (\u00b1\u200913) were included in the univariate analysis. No statistically significant differences were observed in demographic, histopathologic, biochemical, clinical, radiological, or treatment-related factors between patients who experienced tumor regrowth and those who did not (Table\u00a01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study did not identify any predictors of tumor regrowth in patients undergoing NOM after TNT. The limited number of events severely restricted the power to detect statistically meaningful associations. Nevertheless, this area warrants further investigation to better tailor surveillance strategies and optimize NOM recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-025-01342-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:25:55Z","timestamp":1762161955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Tumor Regrowth in Patients Undergoing Non-Operative Management after Total Neoadjuvant Therapy"],"prefix":"10.1007","volume":"56","author":[{"given":"Kamil","family":"Erozkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Steinhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Henke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan","family":"Costedio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Eva","family":"Selfridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish E.","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"2","key":"1342_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","volume":"16","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200\u20137.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1342_CR2","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/annonc\/mdx351","volume":"28","author":"D Azria","year":"2017","unstructured":"Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, et al. Late toxicities and clinical outcome at 5 years of the ACCORD 12\/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28(10):2436\u201342.","journal-title":"Ann Oncol"},{"issue":"1","key":"1342_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1342_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702\u201315.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1342_CR5","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546\u201356.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.gassur.2024.07.015","volume":"28","author":"K Erozkan","year":"2024","unstructured":"Erozkan K, Elamin D, Tasci ME, Liska D, Valente MA, Alipouriani A, et al. Evaluating complete response rates and predictors in total neoadjuvant therapy for rectal cancer. J Gastrointest Surg. 2024;28(10):1605\u201312.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"1342_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II opra trial. J Clin Oncol. 2024;42(5):500\u20136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1342_CR8","doi-asserted-by":"publisher","first-page":"e2448682","DOI":"10.1001\/jamanetworkopen.2024.48682","volume":"7","author":"BK Hilty Chu","year":"2024","unstructured":"Hilty Chu BK, Loria A, Dhimal T, Cai X, Gao S, Li Y, et al. Challenges of surveillance in implementing nonoperative management for rectal cancer. JAMA Netw Open. 2024;7(12):e2448682\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1342_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5445","volume":"8","author":"E Fokas","year":"2022","unstructured":"Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.","journal-title":"JAMA Oncol"},{"key":"1342_CR10","unstructured":"National Comprehensive Cancer Network Guidelines Rectal Cancer Version 2. 2025 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1461"},{"issue":"10139","key":"1342_CR11","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","volume":"391","author":"MJM van der Valk","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the international watch & wait database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537\u201345.","journal-title":"Lancet"},{"issue":"1","key":"1342_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/DCR.0000000000002494","volume":"66","author":"LM Fernandez","year":"2023","unstructured":"Fernandez LM, S\u00e3o Juli\u00e3o GP, Renehan AG, Beets GL, Papoila AL, Vailati BB, et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the international watch and wait database. Dis Colon Rectum. 2023;66(1):41\u20139.","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"1342_CR13","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1097\/SLA.0000000000003738","volume":"274","author":"ME van der Sande","year":"2021","unstructured":"van der Sande ME, Figueiredo N, Beets GL. Management and outcome of local regrowths in a Watch-and-wait prospective cohort for complete responses in rectal cancer. Ann Surg. 2021;274(6):e1056\u201362.","journal-title":"Ann Surg"},{"issue":"12","key":"1342_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","volume":"3","author":"SA Chadi","year":"2018","unstructured":"Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/DCR.0000000000001337","volume":"62","author":"A Habr-Gama","year":"2019","unstructured":"Habr-Gama A, S\u00e3o Juli\u00e3o GP, Vailati BB, Fernandez LM, Ortega CD, Figueiredo N, et al. Organ preservation among patients with clinically node-positive rectal cancer: is it really more dangerous? Dis Colon Rectum. 2019;62(6):675\u201383.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"1342_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.48","volume":"6","author":"K Trumpi","year":"2017","unstructured":"Trumpi K, Ubink I, Trinh A, Djafarihamedani M, Jongen JM, Govaert KM, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis. 2017;6(7):e357.","journal-title":"Oncogenesis"},{"issue":"18","key":"1342_CR17","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-19-0908","volume":"25","author":"SC Kamran","year":"2019","unstructured":"Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, et al. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res. 2019;25(18):5561\u201371.","journal-title":"Clin Cancer Res"},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","volume":"60","author":"C D\u2019Alterio","year":"2020","unstructured":"D\u2019Alterio C, Scala S, Sozzi G, Roz L, Bertolini G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol. 2020;60:351\u201361.","journal-title":"Semin Cancer Biol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01342-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:25:57Z","timestamp":1762161957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01342-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01342-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"25 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}